Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient clinical characteristics

From: Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

  TCHL study (n = 88) Sequencing and pCR data available (n = 69) Sequencing, PTEN and pCR data available (n = 45)
Characteristic No. of patients % No. of patients % No. of patients %
ER status
 Negative 35 39.8 28 40.6 19 42.2
 Positive 53 60.2 41 59.4 26 57.8
PR status
 Negative 54 61.4 39 56.5 29 64.4
 Positive 34 38.6 30 43.5 16 35.6
pCR
 Yes 38 43.2 32 46.4 21 46.7
 No 41 46.6 37 53.6 24 53.3
 Unknown 9 10.2
Targeted therapy
 Trastuzumab 38 43.2 30 43.5 21 46.7
 Lapatinib 10 11.4 10 14.5 6 13.3
 Trastuzumab + lapatinib 40 45.4 29 42 18 40
Age, years
 <49 41 46.6 36 52.2 25 55.6
 ≥49 47 53.4 33 47.8 20 44.4
Tumour size, cm
 ≤5 56 63.6 46 66.7 30 66.7
 >5 23 26.1 17 24.6 12 26.6
 Unknown 9 10.3 6 8.7 3 6.7
N stage
 N0 25 28.4 20 29 9 20
 N1 50 56.8 40 58 31 68.9
 N2 2 2.3 1 1.4 1 2.2
 NX 2 2.3 2 2.9 1 2.2
 Unknown 9 10.2 6 8.7 3 6.7
M stage
 M0 88 100 69 100 45 100
Overall stage
 IIA 30 34.1 26 37.7 12 26.6
 IIB 31 35.2 25 36.2 21 46.7
 IIIA 7 8 4 5.8 3 6.7
 IIIB 10 11.4 8 11.6 6 13.3
 IIIC 1 1.1 0 0 0 0
 Unknown 9 10.2 6 8.7 3 6.7
  1. Abbreviations: ER Oestrogen receptor, PR Progesterone receptor, pCR, Pathological complete response; PTEN Phosphatase and tensin homolog, TCHL Docetaxel, carboplatin, trastuzumab, lapatinib
  2. A total of 88 patients were enrolled in the TCHL phase II neoadjuvant study. After quality control, 74 patient samples were genotyped. Of these 74 samples, pCR data were available for 69 patients. Forty-five tumour samples had sufficient material for PTEN analysis. The clinical characteristics of these three patient groups are shown